(JNJ) Johnson & Johnson - Overview
Sector: HealthcareIndustry: Drug Manufacturers - General | Exchange NYSE (USA) | Currency USD | Market Cap: 578.207m | Total Return 51.5% in 12m
Stock: Medicines, Medical Devices, Consumer Health
Total Rating 75
Risk 86
Buy Signal 0.16
| Risk 5d forecast | |
|---|---|
| Volatility | 16.5% |
| Relative Tail Risk | -5.37% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.05 |
| Alpha | 49.01 |
| Character TTM | |
|---|---|
| Beta | -0.051 |
| Beta Downside | 0.054 |
| Drawdowns 3y | |
|---|---|
| Max DD | 15.95% |
| CAGR/Max DD | 1.22 |
EPS (Earnings per Share)
Revenue
Description: JNJ Johnson & Johnson March 04, 2026
Johnson & Johnson operates in the healthcare sector, developing and selling a broad range of products globally. The companys business model is diversified across two primary segments.
The Innovative Medicine segment focuses on pharmaceuticals for various therapeutic areas, including oncology and immunology. Pharmaceutical companies typically invest heavily in research and development, with long product development cycles.
The MedTech segment provides medical devices and technologies for surgery, orthopedics, and vision care. This segment often involves direct sales to hospitals and healthcare providers, a common distribution model for medical technology firms. To further understand JNJs competitive landscape, consider exploring market share data on ValueRay.
Headlines to watch out for
- Innovative Medicine segment drug approvals drive revenue growth
- MedTech segment product innovation expands market share
- Litigation and regulatory actions increase operational costs
- Global healthcare spending trends impact demand
- Research and development pipeline success fuels future growth
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 26.80b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA -0.14 > 1.0 |
| NWC/Revenue: 1.59% < 20% (prev 6.27%; Δ -4.68% < -1%) |
| CFO/TA 0.12 > 3% & CFO 24.53b > Net Income 26.80b |
| Net Debt (28.22b) to EBITDA (39.85b): 0.71 < 3 |
| Current Ratio: 1.03 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.44b) vs 12m ago 0.49% < -2% |
| Gross Margin: 72.78% > 18% (prev 0.69%; Δ 7.21k% > 0.5%) |
| Asset Turnover: 49.66% > 50% (prev 49.32%; Δ 0.35% > 0%) |
| Interest Coverage Ratio: 33.55 > 6 (EBITDA TTM 39.85b / Interest Expense TTM 971.0m) |
Altman Z'' 5.37
| A: 0.01 (Total Current Assets 55.62b - Total Current Liabilities 54.13b) / Total Assets 199.21b |
| B: 0.85 (Retained Earnings 168.98b / Total Assets 199.21b) |
| C: 0.17 (EBIT TTM 32.58b / Avg Total Assets 189.66b) |
| D: 1.34 (Book Value of Equity 157.17b / Total Liabilities 117.67b) |
| Altman-Z'' Score: 5.37 = AAA |
Beneish M -3.11
| DSRI: 0.86 (Receivables 17.18b/18.93b, Revenue 94.19b/88.82b) |
| GMI: 0.95 (GM 72.78% / 69.07%) |
| AQI: 1.05 (AQ_t 0.60 / AQ_t-1 0.58) |
| SGI: 1.06 (Revenue 94.19b / 88.82b) |
| TATA: 0.01 (NI 26.80b - CFO 24.53b) / TA 199.21b) |
| Beneish M-Score: -3.11 (Cap -4..+1) = AA |
What is the price of JNJ shares?
As of March 29, 2026, the stock is trading at USD 240.45 with a total of 7,615,336 shares traded.
Over the past week, the price has changed by +2.16%, over one month by -3.21%, over three months by +16.46% and over the past year by +51.50%.
Over the past week, the price has changed by +2.16%, over one month by -3.21%, over three months by +16.46% and over the past year by +51.50%.
Is JNJ a buy, sell or hold?
Johnson & Johnson has received a consensus analysts rating of 3.75.
Therefor, it is recommend to hold JNJ.
- StrongBuy: 7
- Buy: 4
- Hold: 13
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the JNJ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 241.1 | 0.3% |
| Analysts Target Price | 241.1 | 0.3% |
JNJ Fundamental Data Overview March 27, 2026
P/E Trailing = 21.7328
P/E Forward = 20.4082
P/S = 6.1385
P/B = 6.9523
P/EG = 1.6448
Revenue TTM = 94.19b USD
EBIT TTM = 32.58b USD
EBITDA TTM = 39.85b USD
Long Term Debt = 39.44b USD (from longTermDebt, last quarter)
Short Term Debt = 8.49b USD (from shortTermDebt, last quarter)
Debt = 47.93b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 28.22b USD (from netDebt column, last quarter)
Enterprise Value = 620.15b USD (578.21b + Debt 47.93b - CCE 5.99b)
Interest Coverage Ratio = 33.55 (Ebit TTM 32.58b / Interest Expense TTM 971.0m)
EV/FCF = 31.48x (Enterprise Value 620.15b / FCF TTM 19.70b)
FCF Yield = 3.18% (FCF TTM 19.70b / Enterprise Value 620.15b)
FCF Margin = 20.91% (FCF TTM 19.70b / Revenue TTM 94.19b)
Net Margin = 28.46% (Net Income TTM 26.80b / Revenue TTM 94.19b)
Gross Margin = 72.78% ((Revenue TTM 94.19b - Cost of Revenue TTM 25.64b) / Revenue TTM)
Gross Margin QoQ = 86.37% (prev 69.56%)
Tobins Q-Ratio = 3.11 (Enterprise Value 620.15b / Total Assets 199.21b)
Interest Expense / Debt = 0.92% (Interest Expense 441.0m / Debt 47.93b)
Taxrate = 17.73% (5.78b / 32.58b)
NOPAT = 26.80b (EBIT 32.58b * (1 - 17.73%))
Current Ratio = 1.03 (Total Current Assets 55.62b / Total Current Liabilities 54.13b)
Debt / Equity = 0.59 (Debt 47.93b / totalStockholderEquity, last quarter 81.54b)
Debt / EBITDA = 0.71 (Net Debt 28.22b / EBITDA 39.85b)
Debt / FCF = 1.43 (Net Debt 28.22b / FCF TTM 19.70b)
Total Stockholder Equity = 79.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.13% (Net Income 26.80b / Total Assets 199.21b)
RoE = 33.78% (Net Income TTM 26.80b / Total Stockholder Equity 79.35b)
RoCE = 27.43% (EBIT 32.58b / Capital Employed (Equity 79.35b + L.T.Debt 39.44b))
RoIC = 20.85% (NOPAT 26.80b / Invested Capital 128.54b)
WACC = 5.41% (E(578.21b)/V(626.14b) * Re(5.80%) + D(47.93b)/V(626.14b) * Rd(0.92%) * (1-Tc(0.18)))
Discount Rate = 5.80% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 33.33 | Cagr: 0.17%
[DCF] Terminal Value 86.32% ; FCFF base≈19.04b ; Y1≈19.00b ; Y5≈20.06b
[DCF] Fair Price = 235.9 (EV 596.32b - Net Debt 28.22b = Equity 568.09b / Shares 2.41b; r=6.0% [WACC]; 5y FCF grow -0.87% → 3.0% )
EPS Correlation: -3.03 | EPS CAGR: -2.16% | SUE: 0.0 | # QB: 0
Revenue Correlation: 11.28 | Revenue CAGR: 1.27% | SUE: 1.56 | # QB: 1
EPS next Quarter (2026-06-30): EPS=2.89 | Chg7d=+0.003 | Chg30d=+0.003 | Revisions Net=+1 | Analysts=16
EPS current Year (2026-12-31): EPS=11.54 | Chg7d=+0.008 | Chg30d=+0.008 | Revisions Net=+4 | Growth EPS=+7.0% | Growth Revenue=+6.9%
EPS next Year (2027-12-31): EPS=12.58 | Chg7d=+0.013 | Chg30d=+0.031 | Revisions Net=+6 | Growth EPS=+9.0% | Growth Revenue=+5.6%
[Analyst] Revisions Ratio: +0.33 (2 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.3% (Discount Rate 7.9% - Earnings Yield 4.6%)
[Growth] Growth Spread = +2.3% (Analyst 5.6% - Implied 3.3%)
P/E Forward = 20.4082
P/S = 6.1385
P/B = 6.9523
P/EG = 1.6448
Revenue TTM = 94.19b USD
EBIT TTM = 32.58b USD
EBITDA TTM = 39.85b USD
Long Term Debt = 39.44b USD (from longTermDebt, last quarter)
Short Term Debt = 8.49b USD (from shortTermDebt, last quarter)
Debt = 47.93b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 28.22b USD (from netDebt column, last quarter)
Enterprise Value = 620.15b USD (578.21b + Debt 47.93b - CCE 5.99b)
Interest Coverage Ratio = 33.55 (Ebit TTM 32.58b / Interest Expense TTM 971.0m)
EV/FCF = 31.48x (Enterprise Value 620.15b / FCF TTM 19.70b)
FCF Yield = 3.18% (FCF TTM 19.70b / Enterprise Value 620.15b)
FCF Margin = 20.91% (FCF TTM 19.70b / Revenue TTM 94.19b)
Net Margin = 28.46% (Net Income TTM 26.80b / Revenue TTM 94.19b)
Gross Margin = 72.78% ((Revenue TTM 94.19b - Cost of Revenue TTM 25.64b) / Revenue TTM)
Gross Margin QoQ = 86.37% (prev 69.56%)
Tobins Q-Ratio = 3.11 (Enterprise Value 620.15b / Total Assets 199.21b)
Interest Expense / Debt = 0.92% (Interest Expense 441.0m / Debt 47.93b)
Taxrate = 17.73% (5.78b / 32.58b)
NOPAT = 26.80b (EBIT 32.58b * (1 - 17.73%))
Current Ratio = 1.03 (Total Current Assets 55.62b / Total Current Liabilities 54.13b)
Debt / Equity = 0.59 (Debt 47.93b / totalStockholderEquity, last quarter 81.54b)
Debt / EBITDA = 0.71 (Net Debt 28.22b / EBITDA 39.85b)
Debt / FCF = 1.43 (Net Debt 28.22b / FCF TTM 19.70b)
Total Stockholder Equity = 79.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.13% (Net Income 26.80b / Total Assets 199.21b)
RoE = 33.78% (Net Income TTM 26.80b / Total Stockholder Equity 79.35b)
RoCE = 27.43% (EBIT 32.58b / Capital Employed (Equity 79.35b + L.T.Debt 39.44b))
RoIC = 20.85% (NOPAT 26.80b / Invested Capital 128.54b)
WACC = 5.41% (E(578.21b)/V(626.14b) * Re(5.80%) + D(47.93b)/V(626.14b) * Rd(0.92%) * (1-Tc(0.18)))
Discount Rate = 5.80% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 33.33 | Cagr: 0.17%
[DCF] Terminal Value 86.32% ; FCFF base≈19.04b ; Y1≈19.00b ; Y5≈20.06b
[DCF] Fair Price = 235.9 (EV 596.32b - Net Debt 28.22b = Equity 568.09b / Shares 2.41b; r=6.0% [WACC]; 5y FCF grow -0.87% → 3.0% )
EPS Correlation: -3.03 | EPS CAGR: -2.16% | SUE: 0.0 | # QB: 0
Revenue Correlation: 11.28 | Revenue CAGR: 1.27% | SUE: 1.56 | # QB: 1
EPS next Quarter (2026-06-30): EPS=2.89 | Chg7d=+0.003 | Chg30d=+0.003 | Revisions Net=+1 | Analysts=16
EPS current Year (2026-12-31): EPS=11.54 | Chg7d=+0.008 | Chg30d=+0.008 | Revisions Net=+4 | Growth EPS=+7.0% | Growth Revenue=+6.9%
EPS next Year (2027-12-31): EPS=12.58 | Chg7d=+0.013 | Chg30d=+0.031 | Revisions Net=+6 | Growth EPS=+9.0% | Growth Revenue=+5.6%
[Analyst] Revisions Ratio: +0.33 (2 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.3% (Discount Rate 7.9% - Earnings Yield 4.6%)
[Growth] Growth Spread = +2.3% (Analyst 5.6% - Implied 3.3%)